This section describes just a few of the successful companies that have received funding from the NIAID SBIR/STTR program to help them advance their innovative tec​hnologies.

Current and past SBIR/STTR recipients, submit your own success stories by emailing the NIAID SBIR/STTR team at NIAIDSBIR@mail.nih.gov.

Sanaria, Inc.

Sanaria is a biotechnology company noted for developing whole-parasite sporozoite vaccines against Plasmodium falciparum and Plasmodium vivax malaria. NIAID SBIR funding supported development of the company's malaria vaccine and related products and services. Sanaria recently announced an agreement with the government of Equatorial Guinea and oil industry partners for $48.5 million in funding to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 through 2018.

To learn more about the company's research, go to Sanaria and Addressing a Global Imperative: Malaria Eradication Through Vaccination.

Specific Technologies

Specific Technologies developed in vitro diagnostic systems for rapid identification of cells at the strain level and is applying this fundamental new platform to detecting and characterizing microorganisms during culture. The company’s unique, patented metabolomic signature technology leverages a low-cost printed chemical colorimetric sensor array to identify cell type down to the strain level. NIAID SBIR funding contributed to development and validation of this diagnostic platform.

In April 2016, Specific Technologies launched its flagship instrument, the Spec80 Blood Culture System Combining Detection and ID, at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam.

Find out more about the company's research at Specific Technologies and Combining Detection and ID for Blood Culture. Also see Specific Technologies Announces the Introduction of the Spec80 Blood Culture System Combining Detection and ID at ECCMID 2016.

AmberGen, Inc.

AmberGen is a biomarker discovery and clinical diagnostics company developing tools that enable patient-specific therapeutic regimens. NIAID SBIR awards supported AmberGen's discovery of novel biomarkers that have since been patented and licensed to INOVA Diagnostics for clinical development and use in commercial diagnostics. This work also led to collaborations on other projects with INOVA Diagnostics.

To learn more about the company's research, go to AmberGen. Read about AmberGen's experience with the NIAID SBIR program at Novel Proteomic Arrays of In Vitro Expressed Proteins for Autoimmune Disease and AmberGen and Mass General License Two Novel Autoantigen Biomarkers for Autoimmune Liver Disease to INOVA Diagnostics. 

Current and past SBIR/STTR recipients, submit your own success stories by emailing the NIAID SBIR/STTR team at mailto:NIAIDSBIR@mail.nih.gov.

See the main NIAID Small Business Programs page for funding opportunities, high priority areas, the application process, success stories, and more.